You are here: Home » Companies » News
Business Standard

Pfizer begins application for Canada's approval of Covid-19 pill

The country has identified seven people with the new variant as of Nov. 30.

Pfizer | Coronavirus Vaccine | Canada


Pfizer to acquire oncology specialist Medivation for $ 14 bn

Inc said on Wednesday it had started the real-time submission of its application seeking Health Canada's approval of its oral COVID-19 antiviral drug candidate.

The pill, PF-07321332, is designed to block a key enzyme needed for the coronavirus to multiply.

The move comes after the Canadian government announced on Tuesday that it was in advanced talks with and Merck & Co Inc regarding a purchase agreement for their COVID-19 antiviral drugs, as the country attempts to control the spread of the Omicron coronavirus variant.

The country has identified seven people with the new variant as of Nov. 30.

The drugmaker last month submitted its application seeking U.S. authorization of the experimental pill, which was shown to cut the chance of hospitalization or death for adults at risk of severe disease by 89% in a clinical trial.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, December 02 2021. 02:13 IST